BIMobject AB: BIMobject releases BIMobject® Apps as free source code
Today, BIMobject AB (BIMobject) announces that the BIMobject ® Apps will be offered as free source code. To further strengthen the company's position as the global leader in digital building products, product information, and BIM object distribution, the company will now allow for other corporations to build Apps for the platform BIMobject ® Cloud using a free BIMobject source code.
Since 2012, BIMobject have built several Apps that integrate the entire BIMobject® Cloud in various types of BIM software such as Trimble SketchUp, Graphisoft ArchiCAD, and Autodesk Revit/AutoCAD. The Apps have been downloaded and installed by users more than 150,000 times, creating full integration into their respective BIM software. The Apps give users increased productivity by letting them find and compare products more easily before downloading, update and add information, as well as communicate.
The BIMobject® Apps are also a vital part of the platform BIMobject® Hercules. Unlike the BIMobject® Cloud, it is aimed at large consultants, building owners, governments, and contractors. The free source code allows these bigger organisations further to enhance the capabilities of the Apps by adding, removing, and modifying the features. The result is a fully customised version of the Apps, tailored to the specific needs within a particular corporation or organisation.
"One of our core principles here at BIMobject is scalability. The BIMobject ® Apps - among the most advanced BIM integration solutions - now have room for a whole new level of growth. It will be used either internally or to add even more value to the existing Apps functionality, pushing the envelope for integrated digital product information", says Stefan Larsson, CEO and founder of BIMobject.
BIMobject aims to maintain its position as the most popular BIM content platform worldwide, serving as a Single Source of Truth for its over 550,000 registered users and more than 1,000 hosted building product manufacturers. The company strives to offer the most dynamic digital content services for manufacturers to form a powerful digital strategy and deliver product information earlier in the BIM process.
Using the BIMobject® Apps to connect BIM software to the BIMobject® Cloud results in an unbroken flow of information and a streamlined workflow, which is why BIMobject has invested a great deal of resources in the Apps. In recent years, BIM software providers such as Vectorworks, Allplan, and Archline, have received the source code as part of individual agreements in order fully to integrate their technology with the BIMobject® Cloud.
Now, the strategic decision has been made to give away the source code and make it available to more stakeholders in the BIM process, such as big design firms, contractors, governments, and other large-scale 3rd party developers. This will further strengthen BIMobject's position on the global market and broaden the user base. Larger businesses will be able to use the Apps and the BIMobject® Cloud for efficient corporate standardisation.
"Some of our competitors charge their app users. We decided to go the other way, because we believe in making our solutions accessible and available to every user in the global BIM community", says Stefan Larsson.
The source code will be provided upon application after a review of the applicant's intended use, as it will not be given to any competitor or allow usage to create a competing service. BIMobject will continue to innovate and add features to the current Apps standard, which will coexist with the new approach and form a complement to the developer cloud API now available for the BIMobject® Cloud.
For more information, please contact:
Louise Otto - Press contact
Tel: +46 40 - 685 29 00
BIMobject® is a Swedish technology company with a global presence operating at the forefront of digitalising the building industry. BIMobject provides a cloud-based platform and powerful technology to make digital product information available for Building Information Modelling (BIM), allowing its use early in the building process for visualisation, specification, and analysis. The platform collects valuable data that streamlines the construction industry throughout the product lifecycle. More intelligent design and construction lead to better product selections, reduced waste, and more efficient logistics during the building process. At the same time, property management benefits from higher quality, improved use of energy, and lower operating costs.
Today, BIMobject operates in a number of markets and has a global growth strategy. The company's offerings include development, hosting, management, and publishing of digital versions of manufacturer products: BIM objects. Its customers are building and interior product manufacturers who market their products via the BIMobject® Cloud. The user base consists primarily of architects, designers, and engineers, who access the BIMobject® Cloud through CAD/BIM-applications, apps, and web services. The BIM objects are integrated into a detailed model of the building, which increases the chance that the real products will be selected for purchase.
BIMobject is a public company listed on Nasdaq Stockholm First North with the ticker symbol BIM.
Certified Adviser: Sedermera Fondkommission
This is an English version of an original Swedish press release communicated by BIMobject AB. In case of interpretation issues or possible differences between the different versions, the Swedish version shall apply.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: BIMobject AB via Globenewswire
Följ NASDAQ OMX
Abonnera på våra pressmeddelanden.
Senaste pressmeddelandena från NASDAQ OMX
ERYTECH Pharma Reports Voting Results from Annual General Meeting Held on June 28, 201817.7.2018 22:30 | Pressmeddelande
LYON, France and CAMBRIDGE, Mass., July 17, 2018 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext:ERYP) (Nasdaq:ERYP) announced that its 2018 Annual General Meeting was held in Lyon on Thursday, June 28, 2018. At the meeting, all resolutions for which management recommended a vote in favor, were adopted, including: - Approval of the annual financial statements and consolidated financial statements for the year ended December 31, 2017 and quietus of directors; - Allocation of the financial year's results; - Approval of regulatory agreements and commitments referred to in Article L.225-38 of the French Commercial Code; - Approval of the regulations of the share subscription and/or purchase options plan adopted by the Board of Directors on June 27, 2017; - Authorization for the Board of Directors to grant share subscription and/or share purchase options and/or to issue detachable share subscription warrants to corporate officers and employees of the Company or companies in the ERYTECH Pharma
Williams Scotsman Receives Competition Bureau Clearance for ModSpace Acquisition17.7.2018 22:15 | Pressmeddelande
BALTIMORE, July 17, 2018 (GLOBE NEWSWIRE) -- WillScot Corporation (NASDAQ:WSC) ("Williams Scotsman"), a specialty rental services market leader providing innovative modular space and portable storage solutions across North America, today announced that, on July 16, 2018, the Canadian Competition Bureau issued a No Action Letter relating to Williams Scotsman's proposed acquisition of Modular Space Corporation ("ModSpace"). WillScot has now obtained the regulatory approvals required to complete the acquisition and continues to progress towards closing in the third quarter of 2018. About Williams Scotsman Headquartered in Baltimore, Maryland, WillScot Corporation is the public holding company for the Williams Scotsman family of companies in the United States, Canada and Mexico. WillScot Corporation trades on the NASDAQ stock exchange under the ticker symbol "WSC." Williams Scotsman is a specialty rental services market leader providing innovative modular space and portable storage solutio
Minerva Neurosciences Elects Jeryl Hilleman to Board of Directors17.7.2018 22:05 | Pressmeddelande
WALTHAM, Mass., July 17, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced the election of Jeryl Hilleman to the Board of Directors of the Company. "Jeri brings a broad life sciences background to Minerva that includes high growth commercial biopharma, med-tech and data science companies," said William F. Doyle, Lead Independent Director of Minerva. "Her track record of delivering strategic and financial growth through execution, strategic partnering and multiple acquisitions will serve Minerva well as the Company completes five ongoing late-stage clinical trials with roluperidone, seltorexant and MIN-117." Ms. Hilleman is presently Chief Financial Officer of Intersect ENT (NASDAQ:XENT), a medical device company with commercial products for the treatment of chronic sinusitis. Previously, she served as CFO of several public
Orion Biotechnology Awarded a $2M Grant from National Center for Research and Development to Fund Further Development of its HIV Microbicide17.7.2018 21:00 | Pressmeddelande
OTTAWA, July 17, 2018 (GLOBE NEWSWIRE) -- Orion Biotechnology Canada Ltd., a developer of novel medical treatments, today announced that its European subsidiary, Orion Biotechnology Polska Sp. z o.o., was awarded a grant of $2M US dollars by the National Center for Research and Development . The grant will fund a project to advance development of the company's innovative microbicide candidate (OB-002H). Designed to prevent the transmission of HIV, OB-002H has the potential to address an urgent and growing need for an HIV prevention product that is affordable, appealing to use, and easily integrates into the lifestyles of people at risk for HIV infection regardless of age, sex or gender. The project is co-financed by the National Center for Research and Development under the InnoNeuroPharm program - Measure 1.2: Sectoral R & D programs of the Intelligent Development Operational Program 2014-2020. Orion Biotechnology will use the grant to complete IND enabling studies, advance OB-002H to
Greater Anglia Selects PowerPlan to Optimise Its Asset Investments17.7.2018 15:29 | Pressmeddelande
ATLANTA, July 17, 2018 (GLOBE NEWSWIRE) -- Greater Anglia, a UK-based train operating company, has selected PowerPlan's Asset Investment Optimization software suite to maximise its asset investments over a 40-year time period. Greater Anglia's long-term investment strategy includes a 40-year asset plan to meet its regulatory requirements. For what was historically built with manual processes and not easily tracked, the Asset Investment Optimization solution from PowerPlan will provide a comprehensive, auditable approach to help the company analyze different investment scenarios for impacts to risk, cost, timing and level of service and provide a defendable asset plan for the next four decades. "The condition of our assets drives our business," said Richard Turner, Head of Asset Management for Greater Anglia. "With PowerPlan, we can apply a fact-based methodology to prioritise investments, maximise their return and produce plans that communicate our asset strategy to internal and extern
Oxford Immunotec Schedules Second Quarter 2018 Earnings Release and Conference Call for July 31, 201817.7.2018 14:30 | Pressmeddelande
OXFORD, United Kingdom and MARLBOROUGH, Mass., July 17, 2018 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company, today announced that it plans to release second quarter 2018 financial results prior to market open on Tuesday, July 31, 2018. Dr. Peter Wrighton-Smith, Chief Executive Officer, and Rick Altieri, Chief Financial Officer, will host a conference call to review the Company's results at 8:00 a.m. Eastern Time the same day. The call will be concurrently webcast. To listen to the conference call on your telephone, please dial (855) 363-5047 for United States callers or +1 (484) 365-2897 for international callers and reference confirmation code 9268558, approximately ten minutes prior to start time. To access the live audio webcast or subsequent archived recording, visit the Investor Relations section of Oxford Immunotec's website at www.oxfordimmunotec.com. The replay will be available on the Company's website for approximately
I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.Besök vårt pressrum